Karissa Alkhafi
Acute Care · Phoenix, AZNPI 1598391500
Payments from drug & device makers
Across 45 payments — averaging $18.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$141
- AbbVie$83
- Array Biopharma Inc$81
- Pharmacyclics LLC, An Abbvie Company$70
- Pfizer$59
- Dexcom, Inc.$48
- plus $359 from 18 others
What the payments were for
- Food & beverage$840100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 7 | $141 |
| AbbVie | 4 | $83 |
| Array Biopharma Inc | 5 | $81 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $70 |
| Pfizer | 3 | $59 |
| Dexcom, Inc. | 2 | $48 |
| AstraZeneca | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $30 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Karyopharm Therapeutics Inc. | 1 | $24 |
| Clovis Oncology, Inc. | 1 | $23 |
| Eisai Inc. | 1 | $21 |
| Gilead | 1 | $19 |
| Myovant Sciences Inc. | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Merck | 1 | $18 |
| Morphosys, US Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $18 |
| Johnson & Johnson | 1 | $18 |
| Novo Nordisk | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Tersera Therapeutics LLC | 1 | $16 |
| CSL Behring | 1 | $14 |
| Lilly USA, LLC | 1 | $12 |
How this compares
$840 in reported general payments places this provider in the 60th percentile of 482 acute care providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 18 | $618 |
| Levothyroxine Sodium | 37 | $520 |
| Atorvastatin Calcium | 25 | $366 |
| Pantoprazole Sodium | 15 | $267 |
| Metformin Hcl | 21 | $260 |
| Losartan Potassium | 21 | $217 |
| Gabapentin | 12 | $185 |
| Quetiapine Fumarate | 13 | $66 |
Paid to pharmacies, not to this prescriber.
Other acute care in Phoenix
- Kim KrmpoticPhoenix$79K
- Laura Cook-GongoraPhoenix$32K
- Cathy PaynePhoenix$26K
- Chandra SorrellePhoenix$16K
- Nicole RauscherPhoenix$12K
- Brooke GambinoPhoenix$11K
- Kelly WesselhoffPhoenix$9K
- Jenna GonzalesPhoenix$8K
- Kristen HudsonPhoenix$8K
- Tammy TyreePhoenix$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.